FIRST-LINE AVASTIN IN LUNG CANCER
Professor Jean-Charles Soria reviews efficacy and safety data for Avastin
plus chemotherapy across clinical trials
in NSCLC.
SAiL results published
Avastin provides a median OS of 14.6 months
with a range of chemotherapies in NSCLC.
The SAiL experience
SAiL investigator Professor Lucio Crino discusses the clinical relevance
of newly reported data for Avastin in NSCLC.
All patient
subgroups
can benefit
from Avastin.
Learn more.
Combining
Avastin with
conventional
chemotherapy.
Learn more.
Click here for a listing of upcoming oncology congresses.
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.